191 related articles for article (PubMed ID: 36028328)
21. Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum.
Lehmann S; Schraen-Maschke S; Vidal JS; Blanc F; Paquet C; Allinquant B; Bombois S; Gabelle A; Delaby C; Hanon O;
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139190
[TBL] [Abstract][Full Text] [Related]
22. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
23. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
24. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
25. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
26. Follow-up Comparisons of Two Plasma Biomarkers of Alzheimer's Disease, Neurofilament Light Chain, and Oligomeric Aβ: A Pilot Study.
Shim Y
Curr Alzheimer Res; 2023; 20(10):715-724. PubMed ID: 38299421
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
29. Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
Gertje EC; Janelidze S; van Westen D; Cullen N; Stomrud E; Palmqvist S; Hansson O; Mattsson-Carlgren N
Neurology; 2023 Apr; 100(17):e1812-e1824. PubMed ID: 36882326
[TBL] [Abstract][Full Text] [Related]
30. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
[TBL] [Abstract][Full Text] [Related]
31. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
32. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
33. β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.
Rosenberg A; Öhlund-Wistbacka U; Hall A; Bonnard A; Hagman G; Rydén M; Thunborg C; Wiggenraad F; Sandebring-Matton A; Solomon A; Kivipelto M
Neurology; 2022 Nov; 99(19):e2102-e2113. PubMed ID: 36130840
[TBL] [Abstract][Full Text] [Related]
34. The implications of different approaches to define AT(N) in Alzheimer disease.
Mattsson-Carlgren N; Leuzy A; Janelidze S; Palmqvist S; Stomrud E; Strandberg O; Smith R; Hansson O
Neurology; 2020 May; 94(21):e2233-e2244. PubMed ID: 32398359
[TBL] [Abstract][Full Text] [Related]
35. Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia.
Naudé PJW; Ramakers IHGB; van der Flier WM; Jiskoot LC; Reesink FE; Claassen JAHR; Koek HL; Eisel ULM; De Deyn PP
Neurobiol Aging; 2021 Nov; 107():1-10. PubMed ID: 34365256
[TBL] [Abstract][Full Text] [Related]
36. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
37. Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau.
Dickerson BC; Wolk DA;
Front Aging Neurosci; 2013; 5():55. PubMed ID: 24130528
[TBL] [Abstract][Full Text] [Related]
38. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
van Maurik IS; Vos SJ; Bos I; Bouwman FH; Teunissen CE; Scheltens P; Barkhof F; Frolich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Frisoni GB; Spiru L; Freund-Levi Y; Wallin AK; Hampel H; Soininen H; Tsolaki M; Verhey F; Kłoszewska I; Mecocci P; Vellas B; Lovestone S; Galluzzi S; Herukka SK; Santana I; Baldeiras I; de Mendonça A; Silva D; Chetelat G; Egret S; Palmqvist S; Hansson O; Visser PJ; Berkhof J; van der Flier WM;
Lancet Neurol; 2019 Nov; 18(11):1034-1044. PubMed ID: 31526625
[TBL] [Abstract][Full Text] [Related]
39. Subjective Spatial Navigation Complaints - A Frequent Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease.
Cerman J; Andel R; Laczo J; Vyhnalek M; Nedelska Z; Mokrisova I; Sheardova K; Hort J
Curr Alzheimer Res; 2018; 15(3):219-228. PubMed ID: 29165083
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
